Identification of an alpha-1 antitrypsin variant with enhanced specificity for factor XIa by phage display, bacterial expression, and combinatorial mutagenesis

Autor: Varsha Bhakta, Mostafa Hamada, Amy Nouanesengsy, Jessica Lapierre, Darian L. Perruzza, William P. Sheffield

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)

Abstract Coagulation Factor XIa (FXIa) is an emerging target for antithrombotic agent development. The M358R variant of the serpin alpha-1 antitrypsin (AAT) inhibits both FXIa and other proteases. Our aim was to enhance the specificity of AAT M358R f

Externí odkaz: https://doaj.org/article/4657582d6d9b43608bea58dc7f4701aa

Multivalency Transforms SARS-CoV-2 Antibodies Into Ultrapotent Neutralizers

Autor: Samir Benlekbir, Katherine Prieto, Krithika Muthuraman, Furkan Guvenc, Edurne Rujas, Jean-Philippe Julien, Natasha Christie-Holmes, Jacob Glanville, Gregory A. Wasney, Patrick Budylowski, Samira Mubareka, Sawsan Youssef, Anthony Semesi, Amy Nouanesengsy, Clare Burn Aschner, Scott D. Gray-Owen, John L. Rubinstein, Hong Cui, Stephanie A. Bueler, Yong Zi Tan, Taylor Sicard, Sindy Liao-Chan, Bebhinn Treanor, Iga Kucharska, Jocelyn C. Newton, Tiantian Zhao

Publikováno v: Addi. Archivo Digital para la Docencia y la Investigación
instname
Digital.CSIC: Repositorio Institucional del CSIC
Consejo Superior de Investigaciones Científicas (CSIC)
Nature Communications
Addi: Archivo Digital para la Docencia y la Investigación
Universidad del País Vasco
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Digital.CSIC. Repositorio Institucional del CSIC

SARS-CoV-2, the virus responsible for COVID-19, has caused a global pandemic. Antibodies can be powerful biotherapeutics to fight viral infections. Here, we use the human apoferritin protomer as a modular subunit to drive oligomerization of antibody

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5722cdeb8e6fa77a947f721a9d3ec314
http://hdl.handle.net/10810/52013